Peripheral zone PSA density: a predominant variable to improve prostate cancer detection efficiency in men with PSA higher than 4 ng ml
- Author:
Cheng WANG
1
;
Yue-Yang WANG
2
;
Shi-Yuan WANG
2
;
Ji-Xiang DING
3
;
Mao DING
2
;
Yuan RUAN
2
;
Xiao-Hai WANG
2
;
Yi-Feng JING
2
;
Bang-Min HAN
2
;
Shu-Jie XIA
2
;
Chen-Yi JIANG
2
;
Fu-Jun ZHAO
2
Author Information
- Publication Type:Journal Article
- Keywords: benign prostate hyperplasia; detection efficiency; peripheral zone prostate-specific antigen density; prostate biopsy; prostate-specific antigen; prostatic neoplasm
- From: Asian Journal of Andrology 2021;23(4):415-420
- CountryChina
- Language:English
- Abstract: To improve the diagnostic efficiency of prostate cancer (PCa) and reduce unnecessary biopsies, we defined and analyzed the diagnostic efficiency of peripheral zone prostate-specific antigen (PSA) density (PZ-PSAD). Patients who underwent systematic 12-core prostate biopsies in Shanghai General Hospital (Shanghai, China) between January 2012 and January 2018 were retrospectively identified (n = 529). Another group of patients with benign prostatic hyperplasia (n = 100) were randomly preselected to obtain the PSA density of the non-PCa cohort (N-PSAD). Prostate volumes and transition zone volumes were measured using multiparameter magnetic resonance imaging (mpMRI) and were combined with PSA and N-PSAD to obtain the PZ-PSAD from a specific algorithm. Receiver operating characteristic (ROC) curve analysis was used to assess the PCa detection efficiency in patients stratified by PSA level, and the area under the ROC curve (AUC) of PZ-PSAD was higher than that of PSA, PSA density (PSAD), and transition zone PSA density (TZ-PSAD). PZ-PSAD could amend the diagnosis for more than half of the patients with inaccurate transrectal ultrasonography (TRUS) and mpMRI results. When TRUS and mpMRI findings were ambiguous to predict PCa (PIRADS score ≤3), PZ-PSAD could increase the positive rate of biopsy from 21.7% to 54.7%, and help 63.8% (150/235) of patients avoid unnecessary prostate biopsy. In patients whose PSA was 4.0-10.0 ng ml
